introduct
unpreced
circumst
coronaviru
diseas
covid
pandem
proven
particularli
challeng
due
lack
establish
therapi
treatment
guidelin
although
highli
contagi
infect
sever
acut
respiratori
syndrom
coronaviru
seem
less
virul
sever
acut
respiratori
syndrom
sar
middl
east
respiratori
syndrom
mer
term
morbid
mortal
clinic
manifest
infect
individu
rang
asymptomat
mild
diseas
critic
ill
rapid
deterior
death
treatment
patient
vari
base
diseas
sever
consider
underli
medic
condit
tabl
sever
drug
emerg
candid
treatment
includ
nucleotid
analog
remdesivir
antimalari
chloroquin
hydroxychloroquin
proteas
inhibitor
lopinavirritonavir
interferonhav
also
includ
ongo
clinic
trial
recommend
treatment
time
also
increas
concern
regard
potenti
increas
suscept
patient
take
medic
nonsteroid
antiinflammatori
drug
nsaid
renin
angiotensin
aldosteron
system
raa
antagonist
upregul
angiotensin
convert
enzym
purpos
literatur
review
synthes
avail
inform
regard
treatment
option
resourc
health
care
profession
await
result
ongo
clinic
trial
around
world
author
search
pubm
scopu
articl
use
combin
keyword
covid
treatment
narr
review
summar
effect
current
treatment
option
address
controversi
regard
continu
use
nsaid
certain
antihypertens
medic
impact
reninangiotensin
system
type
studi
evalu
includ
systemat
review
casestudi
clinic
guidelin
refer
includ
studi
also
review
identifi
addit
sourc
studi
written
english
includ
initi
literatur
search
identifi
articl
articl
includ
review
data
includ
articl
summar
report
drugclass
j
u
r
n
l
p
r
e
p
r
f
demonstr
antivir
activ
sever
rna
virus
includ
ebola
sar
mer
vitro
nonhuman
primat
case
report
us
patient
recent
treat
remdesivir
compassion
use
basi
due
worsen
clinic
statu
condit
improv
remark
within
day
initi
treatment
longer
requir
supplement
oxygen
symptom
dri
cough
mild
rhinorrhea
addit
case
report
remdesivir
use
patient
recov
although
data
limit
case
report
remdesivir
may
potenti
candid
therapi
nonhuman
primat
merscov
treat
combin
remdesivir
found
improv
pulmonari
function
reduc
lung
viral
load
compar
treat
lopinavirritonavir
common
advers
effect
report
gastrointestin
natur
well
elev
transaminas
infus
site
reaction
tabl
sever
phase
iii
trial
underway
determin
efficaci
remdesivir
treatment
remdesivir
may
consid
patient
sever
diseas
respiratori
failur
use
conjunct
hydroxychloroquin
due
increas
risk
qt
prolong
fatal
dysrhythmia
although
distribut
drug
initi
limit
compassion
use
clinic
trial
treatment
critic
ill
patient
manufactur
work
expand
access
governmentapprov
program
elimin
need
compassion
use
request
howev
increas
demand
limit
effort
expand
access
favipiravir
nucleosid
analog
inhibit
viral
rna
polymeras
initi
intend
treatment
rna
virus
ebola
influenza
random
control
trial
found
favipiravir
higher
clinic
recoveri
rate
produc
statist
signific
reduct
durat
fever
compar
umifenovir
antivir
drug
use
treatment
influenza
infect
countri
common
advers
effect
abnorm
transaminas
psychiatr
symptom
gastrointestin
discomfort
elev
serum
uric
acid
tabl
ribavirin
typic
use
treatment
hcv
rsv
initi
consid
possibl
therapi
treatment
howev
subsequ
studi
shown
dose
requir
effect
antivir
activ
may
potenti
fatal
advers
effect
hemolyt
anemia
therebi
limit
clinic
use
tabl
favipiravir
ribavirin
current
recommend
treatment
patient
howev
sever
random
trial
investig
antivir
effect
favipiravir
favipiravir
approv
fda
current
avail
use
unit
state
high
risk
toxic
due
ribavirin
therapi
outweigh
potenti
benefit
longer
pursu
potenti
treatment
option
combin
lopinavirritonavir
typic
use
treatment
human
immunodefici
viru
hiv
infect
howev
note
lopinavir
vitro
activ
coronaviru
ritonavir
also
proteas
inhibitor
primari
role
boost
lopinavir
concentr
prolong
halflif
via
cytochrom
inhibit
studi
conduct
found
patient
sarsassoci
coronaviru
treat
combin
proteas
inhibitor
ribavirin
nucleosid
analogu
found
decreas
viral
load
rise
peripher
lymphocyt
count
significantli
lower
advers
event
acut
respiratori
distress
syndrom
ard
death
patient
treat
combin
therapi
also
found
decreas
need
corticosteroid
reduc
risk
nosocomi
infect
compar
patient
given
standard
care
ribavirin
studi
prompt
clinic
trial
determin
effect
use
lopinavirritonavir
treat
conclud
observ
benefit
use
combin
therapi
treatment
sever
infect
subsequ
studi
howev
suggest
earli
administr
lopinavirritonavir
effect
reduc
viral
load
improv
clinic
outcom
patient
mild
moder
diseas
effect
lopinavirritonavir
treat
controversi
time
overal
lopinavirritonavir
associ
higher
rate
gastrointestin
advers
effect
compar
standard
care
patient
sever
infect
requir
discontinu
therapi
combin
lopinavirritonavir
also
known
caus
qt
prolong
concern
regard
multipl
drugdrug
interact
associ
ritonavir
particular
tabl
due
lack
definit
evid
support
use
lopinavirritonavir
high
risk
advers
event
signific
drugdrug
interact
use
agent
recommend
time
result
clinic
trial
world
health
organ
includ
lopinavirritonavir
one
arm
studi
may
provid
conclus
insight
benefit
use
drug
treatment
chloroquin
deriv
hydroxychloroquin
tradit
use
treatment
malaria
certain
autoimmun
diseas
howev
drug
possibl
activ
sarscov
sarscov
vitro
clinic
practic
respect
studi
conduct
found
chloroquin
abil
elev
endosom
ph
therefor
inhibit
phdepend
step
viral
replic
process
effect
mitig
spread
infect
host
cell
chloroquin
also
found
immunomodulatori
effect
suppress
tumor
necrosi
factorand
releas
may
help
prevent
cytokin
storm
lead
rapid
deterior
patient
furthermor
chloroquin
found
show
efficaci
treat
associ
pneumonia
multicent
clinic
trial
patient
china
subsequ
studi
found
hydroxychloroquin
increas
potenc
toler
safeti
profil
compar
chloroquin
recent
nonrandom
clinic
trial
patient
treat
hydroxychloroquin
alon
patient
treat
combin
hydroxychloroquin
azithromycin
substanti
reduct
viral
load
rapid
viru
elimin
seen
patient
treat
combin
hydroxychloroquin
azithromycin
howev
major
patient
treat
hydroxychloroquin
alon
continu
display
symptom
upper
lower
respiratori
tract
infect
data
support
use
drug
limit
best
media
coverag
surround
treatment
prompt
selfmed
compound
contain
chloroquin
effort
prevent
infect
note
use
inappropri
chloroquin
lesser
extent
hydroxychloroquin
toxic
caus
fatal
dysrhythmia
electrolyt
shift
tabl
given
wider
access
antimalari
compar
aforement
antivir
combin
treatment
hydroxychloroquin
azithromycin
recommend
mani
hospit
patient
moder
sever
fda
recent
grant
emerg
author
hydroxychloroquin
treat
infect
although
chloroquin
approv
fda
author
ad
stockpil
use
hospit
result
surg
demand
chloroquin
hydroxychloroquin
india
major
export
agent
restrict
export
precipit
critic
shortag
sever
ongo
clinic
trial
investig
efficaci
prophylact
therapeut
use
medic
ultim
optim
role
drug
yet
elucid
although
corticosteroid
often
use
antiinflammatori
effect
patient
respiratori
infect
sever
studi
indic
use
corticosteroid
patient
associ
delay
viral
clearanc
higher
risk
secondari
infect
increas
risk
mortal
still
use
corticosteroid
may
indic
patient
develop
ard
refractori
septic
shock
underli
respiratori
condit
asthma
chronic
obstruct
pulmonari
diseas
copd
studi
conduct
china
found
use
methylprednisolon
decreas
risk
death
patient
develop
ard
current
recommend
routin
use
corticosteroid
treatment
patient
due
potenti
delay
viral
clearanc
advers
effect
avascular
necrosi
psychosi
tabl
corticosteroid
may
use
indic
refractori
septic
shock
sever
ard
summar
corticosteroid
use
sole
treatment
infect
may
requir
treat
condit
may
accompani
j
u
r
n
l
p
r
e
p
r
f
tocilizumab
sarilumab
monoclon
antibodi
receptor
current
consid
use
patient
develop
cytokin
releas
syndrom
cr
may
potenti
role
sever
lifethreaten
ill
propos
efficaci
treatment
involv
attenu
potenti
fatal
inflammatori
respons
reduc
cytokin
concentr
inhibit
product
acut
phase
reactant
inflammatori
marker
includ
level
monitor
therapi
howev
result
often
avail
time
manner
common
advers
effect
includ
abnorm
transaminas
gastrointestin
perfor
neutropenia
infus
reaction
also
report
tabl
limit
data
support
use
monoclon
antibodi
tocilizumab
sarilumab
patient
develop
evid
associ
cr
may
consid
candid
treatment
use
agent
passiv
immun
use
treat
viral
infect
patient
unabl
develop
adequ
immun
respons
infant
born
mother
activ
hepat
b
viru
infect
metaanalysi
studi
investig
use
convalesc
plasma
treatment
merscov
found
signific
reduct
mortal
viral
load
immedi
advers
event
use
convalesc
plasma
effect
elimin
viral
load
patient
previou
viremia
improv
clinic
condit
critic
ill
patient
patient
resolut
ard
wean
mechan
ventil
within
week
treatment
fda
approv
use
convalesc
plasma
treatment
sever
immedi
lifethreaten
infect
current
sever
trial
conduct
still
recommend
regard
use
convalesc
plasma
remain
controversi
guidelin
suggest
use
critic
ill
patient
state
target
level
neutral
antibodi
titer
unknown
institut
consid
use
structur
studi
indic
virus
abl
bind
target
human
cell
use
receptor
panic
ensu
releas
studi
suggest
patient
take
nsaid
angiotensin
convert
enzym
ace
inhibitor
angiotensin
receptor
blocker
arb
may
increas
express
therefor
increas
risk
sever
infect
nsaid
work
inhibit
cyclooxygenas
cox
therebi
block
product
prostaglandin
import
mediat
fever
inflamm
mechan
nsaid
increas
express
well
understood
howev
fever
report
one
common
clinic
manifest
nsaid
ibuprofen
often
use
antipyret
antiinflammatori
effect
set
infect
although
lack
evid
support
potenti
risk
nsaid
use
patient
may
prudent
use
altern
antipyret
medic
acetaminophen
j
u
r
n
l
p
r
e
p
r
f
concret
data
avail
interestingli
studi
conduct
found
nsaid
indomethacin
potent
inhibitor
replic
dog
suggest
could
benefici
therapi
sar
infect
howev
evid
exist
effect
indomethacin
patient
infect
initi
recommend
use
ibuprofen
sinc
revis
statement
state
either
acetaminophen
ibuprofen
may
use
addit
studi
requir
determin
risk
nsaid
pose
set
infect
time
clinic
evid
suggest
ace
inhibitor
arb
increas
suscept
increas
risk
sever
diseas
alreadi
infect
fact
abruptli
discontinu
treatment
antihypertens
switch
hypertens
medic
may
increas
risk
advers
clinic
outcom
associ
uncontrol
hypertens
lead
cardiolog
organ
advis
discontinu
ace
inhibitor
arb
recommend
physician
assess
clinic
condit
individu
patient
make
chang
treatment
regimen
recent
found
recombin
protein
made
attach
extracellular
domain
fc
region
igg
effect
neutral
vitro
although
research
need
efficaci
fusion
protein
human
could
repres
viabl
option
treatment
although
current
avail
therapi
directli
activ
sever
medic
emerg
potenti
treatment
due
low
cost
easi
access
lack
altern
treatment
option
treatment
combin
hydroxychloroquin
azithromycin
often
consid
hospit
patient
moder
sever
note
use
antimalari
base
singl
studi
small
sampl
size
nonrandom
control
group
signific
drop
treatment
group
efficaci
treatment
still
question
risk
signific
advers
effect
consid
prior
initi
treatment
drug
among
antivir
remdesivir
could
promis
candid
may
wide
avail
upcom
week
passiv
immun
success
use
past
howev
efficaci
convalesc
plasma
treatment
critic
ill
patient
still
larg
unknown
mani
institut
begin
use
treatment
individu
recov
diseas
convalesc
plasma
becom
avail
although
mani
concern
regard
use
medic
ibuprofen
raa
antagonist
patient
current
guidelin
state
ibuprofen
may
use
recommend
discontinu
ace
inhibitor
arb
must
continu
reevalu
current
treatment
recommend
new
data
emerg
discourag
inappropri
prescrib
hoard
medic
time
parallel
effort
also
j
u
r
n
l
p
r
e
p
r
f
focus
vaccin
develop
infect
control
measur
well
optim
respiratori
support
care
tabl
studi
perform
experiment
treatment
option
mani
small
sampl
size
yield
data
statist
signific
mani
treatment
therefor
use
trial
error
basi
base
limit
data
sever
studi
conduct
vitro
nonhuman
primat
therefor
may
applic
use
human
furthermor
review
consid
variat
treat
pediatr
pregnant
older
adult
patient
patient
often
exclud
clinic
trial
pandem
continu
evolv
inform
becom
avail
effect
certain
therapi
still
result
ongo
clinic
trial
test
singl
combin
therapi
need
make
definit
recommend
treatment
howev
result
trial
may
readili
avail
near
futur
peak
pandem
must
underestim
import
effort
slow
transmiss
optim
support
measur
nonfund
studi
compens
conduct
studi
author
financi
interest
relationship
disclos
j
u
r
n
l
p
r
e
p
r
f
patient
underli
condit
diabet
heart
failur
endstag
renal
diseas
immunosuppress
increas
risk
sever
diseas
ard
possibl
death
b
doxycyclin
may
consid
altern
patient
demonstr
hypersensit
reaction
azithromycin
c
hydroxychloroquin
must
discontinu
prior
initi
remdesivir
due
risk
qt
prolong
j
u
r
n
l
p
r
e
p
r
f
recommend
time
guanosin
analog
interfer
viral
replic
hemolyt
anemia
recommend
time
proteas
inhibitor
prevent
product
activ
viral
peptid
gastrointestin
distress
qt
prolong
drugdrug
interact
ritonavir
recommend
time
elev
endosom
ph
inhibit
ph
depend
step
viral
replic
process
electrolyt
imbal
fatal
dysrhythmia
torsad
de
point
may
use
altern
hydroxychloroquin
unavail
elev
endosom
ph
inhibit
ph
depend
step
viral
replic
process
electrolyt
imbal
fatal
dysrhythmia
torsad
de
point
combin
treatment
azithromycin
recommend
patient
moder
sever
diseas
bind
cytoplasm
receptor
chang
transcript
mrna
reduc
product
inflammatori
mediat
avascular
necrosi
psychosi
hyperglycemia
adren
suppress
indic
patient
refractori
septic
shock
sever
ard
recommend
routin
use
block
cox
inhibit
product
prostaglandin
gastrointestin
ulcersbleed
may
upregul
evid
support
use
contraind
may
use
antiinflammatori
antipyret
effect
block
cox
inhibit
product
prostaglandin
gastrointestin
ulcersbleed
may
upregul
evid
antivir
effect
human
may
use
antiinflammatori
antipyret
effect
